Background With growing interest in focal therapy (FT) of prostate cancer (PCa) there is an increasing armamentarium of treatment modalities including high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation (FLA), irreversible electroporation (IRE), vascular targeted photodynamic therapy (VTP), focal brachytherapy (FBT) and stereotactic ablative radiotherapy (SABR). Currently there are no clear recommendations as to which of these technologies are appropriate for individual patient characteristics. Our intention was to review the literature for special aspects of the different technologies that might be of advantage depending on individual patient and tumour characteristics. Methods The current literature on FT was screened for the following factors: morbidity, repeatability, tumour risk category, tumour location, tumour size and prostate volume and anatomical issues. The ESUT expert panel arrived at consensus regarding a position statement on a structured pathway for available FT technologies based on a combination of the literature and expert opinion. Results Side effects were low across different studies and FT modalities with urinary continence rates of 90-100% and erectile dysfunction between 5 and 52%. Short to medium cancer control based on post-treatment biopsies were variable between ablative modalities. Expert consensus suggested that posterior lesions are better amenable to FT using HIFU. Cryotherapy provides best possible outcomes for anterior tumours. Apical lesions, when treated with FBT, may yield the least urethral morbidity. Conclusions Further prospective trials are required to assess medium to long term disease control of different ablative modalities for FT. Amongst different available FT modalities our ESUT expert consensus suggests that some may be better for diffe`rent tumour locations. Tumour risk, tumour size, tumour location, and prostate volume are all important factors to consider and might aid in designing future FT trials.
Introduction
In recent years, there has been rising interest in focal therapy (FT) of prostate cancer (PCa). Advances in imaging and improved understanding of tumour biology has permitted a shift from radical surgery to organ sparing treatment in selected patients [1] , aimed at reducing side effects of radical treatment [2] . With increasing number of patients diagnosed with low-and intermediate risk PCa, the number of patients on active surveillance (AS) is increasing [3] . Recent guidelines recommend AS as the standard of care for very low risk PCa [4] . However, misclassification and uncertainty of time of progression might limit AS. Equally, certain patient-specific factors indicate less favourable risk and some form of intervention is recommended [5] . Utilisation of better risk classification at diagnosis using novel serum and urine biomarkers, tissue-based markers and imaging techniques such as multiparametric magnetic resonance imaging (mpMRI) may aid in stratifying patients to either AS or appropriate intervention in the future. Although many authors consider FT as an adjunct to AS [6] , the indications for FT are expanding and can be placed between AS and radical therapy and as a potential alternative to men with clinically significant PCa that would otherwise progress if left untreated [7] [8] [9] .
The current treatment armamentarium for FT includes high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation (FLA), irreversible electroporation (IRE), vascular targeted photodynamic therapy (VTP), focal brachytherapy (FBT) and stereotactic ablative radiotherapy (SABR). Newer modalities are continuously being explored. However, there are no clear recommendations stating which of the available technologies might be of advantage or disadvantage with respect to individual patient and tumour characteristics. Our clinical review aims to summarise current evidence and outline the special characteristics of different ablative technologies used for FT in order to propose a personalised treatment plan that might be considered depending on individual patient, prostate gland and tumour characteristics helping to design future FT trials.
Materials and methods
We carried out a PubMed search (between April 2016 and November 2017) to identify clinical trials, original articles, reviews, editorials and letters to the editor, addressing FT in PCa. In addition, abstracts from the European Association of Urology, European Society of Medical Oncology, American Urological Association and American Society of Medical Oncology meetings were also searched for relevant studies. Search terms included a combination of PCa and FT, HIFU, cryotherapy, IRE, laser ablation, photodynamic therapy, VTP, external beam radiotherapy and brachytherapy. A list of articles determined to be relevant was circulated among the authors, and final consensus was reached on both structure and the literature. For all treatment technologies, the current literature on FT was especially screened for the following factors: morbidity, repeatability, tumour risk category, tumour location, tumour size and prostate volume, MRI/TRUS fusion and anatomical issues. Based on a combination of literature review and expert opinion the ESUT expert panel arrived at position statement regarding a structured treatment pathway for available FT technologies.
Results
Although FT is gaining popularity both among physicians and patients [10] , a clear discordance exists between the number of review articles and original studies published. PubMed search revealed over 144 reviews and only 28 clinical trials. This lacuna resulted in numerous consensus meetings to be convened in recent years [11] [12] [13] [14] [15] [16] [17] .
Description of available technologies
High intensity focused ultrasound HIFU uses the principle of a convex lens [18] . Using a spherical transducer, ultrasound waves are focused to a target area in order to create coagulation necrosis by thermal and mechanical effects. Two systems have received FDA approval for prostate tissue ablation in 2015: the French Ablatherm system (EDAP-TMS, Vaulx en Velin, France) and the American Sonablate 450 system (SonaCare, Charlotte, North Carolina, USA). FocalOne (EDAP-TMS) is the latest HIFU generation device for the treatment of PCa specifically designed for FT. ExAblate2100 (InSightec Ltd., Haifa, Israel) is a commercially available system that utilises MRI to accurately guide and monitor temperature during treatment [19] . Detailed anatomical MR images facilitate identification of target zones, help in endorectal ultrasound array placement and orientation along with real time MR temperature monitoring. There have been ten studies on focal HIFU that treated between 20 [20] and 111 [21] patients with 12-38 months of follow-up. Posttreatment biopsy proven recurrence rates ranged between 11% at 6 months [20] and 26.5% at 12 months of follow-up [22] with acceptable potency and excellent continence rates.
Cryotherapy
Cryotherapy uses a nadir temperature averaging −40°C for effective cryo-destruction of tissue using 'freeze rupture' [23] i.e. cytolysis through extracellular and intracellular mechanisms. The combined effect of cellular, physical and biochemical insults results in adequate ablation of tumour tissue. Newer devices have been introduced where pressurised gas is used to both freeze (argon gas) and then [33] .
VTP therapy
VTP is a form of nonthermal ablative technique that is based on the interaction between light brought by transperineally inserted intraprostatic laser fibres, a photosensitive agent (PS) administrated orally (aminolevulinic acid (ALA) or motexafin lutetium) or intravenously (TOOKAD or WST-11), and oxygen present in tissues.
Early experience from Taneja et al. [34] and Azzouzi et al. [35] highlighted that this intervention is safe, teachable and repeatable. The challenges of TOOKAD soluble are limited to the accurate placement of needles within the prostate using a grid. A study conducted by Moore et al. [36] showed that the optimal drug dose, light dose and light density index (LDI) for prostate ablation using TOOKAD soluble are 4 mg/kg WST11 activated by 753 nm light at a dose of 200 J/cm and a LDI of ≥1. These parameters applied in a group of 12 men resulted in treatment effect in 95% of the planned treatment volume and a negative biopsy rate of 83% at 6 months. The first multicentre phase III randomised study conducted by Azzouzi et al. [37] showed significant reduction in both cancer progression and need for radical surgery in TOOKAD VTP when compared to patients in AS at 2 years; although cancer was still present in 51% patients in the VTP arm. The results of previous studies with FLA and VTP are summarised in Table 2 .
Focal brachytherapy
Brachytherapy for PCa involves implantation of radioactive I 125 seeds and usage of dynamic dose calculations with continuous feedback as per the actual position of each seed. The volume of prostate to be treated is based on the site of the positive biopsies and on the MRI images.
Cosset et al. [38] treated 21 patients with FBT using a mean focal dose of 145 Gy with an average D90 of 183.2 Gy, and a mean V100 of 99.3%. The mean initial prostate specific antigen (PSA) was 6.9 ng/mL which dropped to 2.6 ng/mL at 12 months. There was a borderline improvement in International Prostate Symptom Score at 6 months and a significantly better International Index of Erectile Function score when compared with comparative historical results of total prostate implants. A study by Barret et al. [39] on 12 patients revealed a drop in mean PSA from 6.2 to 2.8 ng/mL with no significant change in potency and continence at 12 month follow up. Dosimetric calculations by Kamrava et al. [40] revealed that FBT yielded a statistically significant decreased radiation dose to organs at risk and provided complete target coverage with a catheter array designed for whole gland coverage.
External focal beam radiotherapy
The possibility of using external focal beam radiotherapy in its stereotactic form as a FT modality is being explored with newer devices like CyberKnife (Accuray Inc., California, USA) which delivers high-dose hypofractionated stereotactic body radiation using a robotic arm in combination with intrafractional prostate motion tracking [41] . Typical treatment includes 80-200 beams of radiation to focal regions of prostate that are delivered from up to 100 or more positions around the patient. Each beam can be targeted at a unique position within the target volume. The smallest reasonable target volume is around 2 cm 3 . The target volume consisted of a 5-mm expansion zone antero-laterally and 3 mm posteriorly in a study conducted by King et al. [42] . A recent study by MacDougall et al. [43] highlighted that CyberKnife maintained better accuracy and precision when compared to Rapidarc system (Varian Medical Systems, Palo Alto, California, USA) due to its real-time fiducial motion tracking system.
Irreversible electroporation
The treatment effect in IRE is secondary to permanent nanopore formation in the cell membrane leading to apoptosis. With apoptosis, cells are phagocytised by immune cells and then replaced by innate cellular regeneration. This mechanism of cell death has potential to spare the tissue scaffold which prevents scarring which is usually seen in thermal ablative techniques [44] . However, the risk of reflex movements induced by the electrical impulse could induce needle displacement which may cause damage to important functional structures [45] .
The first study to report on the use of IRE in PCa was by Onik and Rubinsky [46] , who treated 16 patients with localised PCa. Patients who were potent before remained so after IRE treatment. However, two patients who received bilateral IRE treatment required 6 months for full return of potency. Van den Bos et al. [47] performed an ablate-andresect study, performing IRE in 16 PCa patients 4 weeks prior to radical prostatectomy. In this study, IRE ablation zones were found to extend beyond the IRE needles, with three needle ablations being up to 2.9 times larger than the needle configuration. Valerio et al. identified suspicious residual disease in six patients (17.6%) using mpMRI following IRE in 34 patients [48] . A more recent study by the same author [49] revealed in field residual disease in 38.9% of patients following IRE. Interestingly, 85.7% of these patients had clinically significant disease.
Discussion

Special characteristics of FT technologies
Morbidity Except for one study by Azzouzi et al. [50] randomising VTP (TOOKAD soluble) against AS, there are there are no other prospective randomised trials comparing morbidity outcomes of any of the FT modality with each other or with standard treatment options. There was higher incidence of grade I and II morbidity (graded by National Cancer Institute Common Terminology Criteria for Adverse Eventsversion 4.03) in VTP when compared to AS in this study. The other published non-comparative reports however indicate a low morbidity profile with FT. It is prudent to note that most studies used heterogeneous methods to assess continence and potency [51] . A retrospective study by Barret et al. [39] comparing adverse effects of the four FT modalities HIFU, cryotherapy, VTP and FBT indicated that focal cryotherapy was responsible for most of the complications. However, the authors conclude that the complication rates decreased with increase in expertise. None of the studies and case reports have reported severe morbidity.
Repeatability
Repeatability of a FT modality may be advantageous for patients who develop local recurrence by avoiding the need for radical treatment and possibly reduce morbidity. Studies have shown that FT performed with different modalities like HIFU [52] and cryotherapy [53] is repeatable. Out of nine patients who had positive biopsy following FT, four men (9.7%) underwent repeat focal HIFU in a study conducted by Ahmed et al. [54] with a reduction in PSA from a median of 3.9 ng/mL (IQR 3.7-4.5) at 6 months (before retreatment) to 2.9 ng/mL (1.8-3.6) at 12 months following FT. No further data was provided on the remaining five patients who opted for AS and post repeat treatment morbidity and changes in quality of life. Cryotherapy was repeated in numerous studies in the past [9, 26, [55] [56] [57] . The number of cycles that can be repeated is being explored. After evaluating the magnitude of spill of radiation dose from a hemigland FBT treatment, Kamrava et al. [40] concluded that retreatment for a central lesion could be difficult using brachytherapy and other salvage options may be considered.
In summary, FT was described to be repeatable in HIFU, cryotherapy and FBT, but none of the studies measured changes in morbidity following retreatment. Future studies looking at this aspect may provide valuable information on the repeatability of FT modalities.
Tumour risk category
Current guidelines do not recommend FT for very low risk disease. Most of the FT modalities have initially been focused on treating low risk disease. The feasibility of primary FT using HIFU and cryotherapy has also been studied in intermediate risk PCa patients with acceptable results [51, 53, 58] . A study by Muto et al. [59] revealed that 2-year biochemical disease-free survival rates after HIFU in patients at high risk were significantly inferior than those in patients at low risk. High risk patients were also included in cryotherapy studies conducted by Ward et al. [24] , Truesdale et al. [25] , Onik et al. [26] and Ellis et al. [57] with poor outcomes in this category of patients. However, there is no evidence from comparative studies showing superiority of any FT modality in treating higher risk disease.
Tumour location
Location of tumour foci is important for choosing the FT modality. Posterior tumours, even in large prostates, are well accessible by a transrectal modality such as HIFU. However, thermal technologies such as HIFU and cryotherapy might not be the first option in apically located tumours given the increase risk of urethral sphincter damage. Post-cryotherapy failures were observed in the exact area where surgeons attempted to protect the urethral mucosa from deep freezing, using a urethral warming catheter with 43°C irrigation [10] . Cryotherapy is not the first choice in posterior lesions since it has been shown that temperatures lower than −20°C are required to destroy tumour cells but collateral cellular damage can occur in normal tissue at −15°C, and in neurovascular tissue, a decrease in autonomic nerve function is seen even at +3°C, becoming irreversible at temperatures below −20°C [18] .
Anterior lesions may be more easily ablated by transperineal needle-based energy such as cryotherapy, FLA and VTP when compared to HIFU [60] . A recent study by Cosset et al. [38] in 21 patients showed extremely low urethral toxicity even while treating apical lesions with FBT. Therefore, apical lesions might be more safely targeted by FBT, minimising damage to the urethral sphincter. Further trials are warranted comparing different FT modalities with respect to location.
Tumour size and prostate volume
Older generation HIFU devices were limited to prostate glands with volume <40 cc due to the limitations in focal distance length [39] . The 3.0 MHz probe in newer devices like Ablatherm creates lesions that are adjustable from 19 to 26 mm in height. It is of disadvantage that the focus point might be outside the prostate in smaller glands, especially in the peripheral zone. The Sonablate probe comprises two different crystals with focal length of 3.0 cm and 4.0 cm. The discrete ablation volume of both these crystals is 10 mm in height. The FocalOne probe has a dynamic focusing transducer that can move the focal point of the transducer to a maximum of eight different points producing a treated zone from 5 up to 40 mm in height. At the end of the treatment, contrast enhanced ultrasound image can be acquired to indicate devascularized ablated areas [61] . Cryotherapy must be used carefully in tumours located in smaller glands [51] since the 'ice ball' may extend into adjacent neurovascular bundle (NVB) or urethra in small prostates increasing the risk of collateral damage [62] . This can be avoided by choosing needles that produce smaller ice-balls. Other modalities like IRE, FLA and FBT do not seem to be restricted by prostate volume for FT approaches.
MRI/TRUS fusion
MRI/TRUS real time fusion during FT procedure is currently possible with the FocalOne [63] and a number of image-fusion software that are normally used for prostate Fig. 1 Schematic representation of the personalised FT approach. FBT focal brachytherapy, FLA focal laser ablation, HIFU highintensity focused ultrasound, IRE irreversible electroporation, PDT photodynamic therapy biopsy have been incorporated into the Sonablate device [64] . These systems can import images such as mpMRI for treatment planning. Although this option is promising, it has some technical limitations: prostate deformation during treatment might impair the accuracy of image fusion. For instance, Shoji et al. [65] showed significant swelling and shift of about 13% for the entire prostate during wholegland HIFU treatment. Difficulties arise when more than one MRI zone is fused for treatment planning. Only limited data is currently available on the biopsy outcomes following this modality [63] .
In-bore MRI interventions
Usage of mpMRI for real time intraoperative guidance is being explored in HIFU, cryotherapy, FLA and brachytherapy [66] . In-bore visualisation of tumour enables accurate targeting of lesions. However, its actual place compared to transrectal guidance in terms of resource use and whether there is an significant advantage is yet to be established. Theoretically, MR guidance in-bore might sound advantageous; however, when MR lesions require 5-9 mm of margin [67] , such precision is unlikely to be needed when the volume of ablation will usually extend to a quadrant of the prostate gland. Magnetic resonance thermometry provides better temperature feedback indicating selective and adequate tumour ablation as well as monitoring sensitive surrounding structures like urethral sphincter and NVB [66] .
Anatomical issues
Rectal abnormality like congenital defects, post anorectal resection or post radiation strictures make transrectal modalities like HIFU and transrectal MR-guided focal laser therapy unusable. Newer platforms using transperineal route without TRUS control but with in-bore MRI guidance like cryotherapy, FLA and brachytherapy may be useful in this situation.
Treatment pathway by the European Section of Urotechnology
Given the numerous primary FT options and its different advantages, there is now increasing interest in developing individualised patient recommendations [68] . We propose a pathway for a personalised treatment plan to ensure optimal utilisation of available technologies. The pathway was developed based on tumour location within the prostate. Posterior lesions are better amenable to FT using HIFU. Cryotherapy provides best possible outcomes for anterior tumours and apical lesions, when treated with FBT, may yield the least urethral morbidity. Recommendations of the personalised approach strategy considering first and secondary choice of options are shown in Figure 1 .
In conclusion, recent studies evaluating FT were able to provide evidence on morbidity and short and medium term oncologic results; mainly based on imaging and re-biopsy. Further prospective trials are required to assess medium to long term disease control of different ablative modalities for FT. The intention of our clinical review was to evaluate if the selection of different FT technologies can be facilitated based on several patient, prostate and tumour characteristics. Based on the current literature on available FT modalities our ESUT expert consensus suggests that some may be better for different tumour locations. Tumour risk, tumour size, tumour location and prostate volume are all important factors to consider and might aid in designing future FT trials.
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